clinical trial · NCT04777331
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease
Hoffmann-La Roche·phase2·active not recruiting·n = 586
Parkinsons DiseasePrasinezumabPlacebo
brief summary
This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD medication.
started
May 5, 2021
primary completion
Sep 11, 2024
completion
Dec 30, 2026
last updated
Mar 9, 2026
official title
A Phase IIB, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol